New fund from Rock Spring Ventures will back sector growth

Rock Spring Ventures today launched a unique £50m venture capital fund focusing on early-stage life science and health technology companies. Based in Scotland, the fund will invest in young companies developing novel approaches to unmet needs in the study and treatment of major diseases and technologies designed to advance better healthcare delivery. The new fund has secured early commitments for more than half of its £50m target from an unprecedented syndicate of international investors. Initial investors include the European Investment Fund (EIF); Scottish Enterprise through the Scottish Investment Bank; Strathclyde Pension Fund; Rock Spring Ventures LP (RSV-US) and the Universities of Glasgow, Edinburgh and Aberdeen. The fund aims to provide venture capital to the most promising life science technologies, including those being spun-out from leading universities. Rock Spring Ventures EU LP (RSV-EU) is led by a sector-specific investment team with significant company-building experience. Managing partners Sinclair Dunlop and (Ms) Kyp Sirinakis have managed three US-based venture funds during the last fifteen years.